tiprankstipranks
Trending News
More News >

Kindstar Globalgene Issues Profit Warning Amid Economic Challenges

Story Highlights
  • Kindstar Globalgene expects a significant loss for 2024 due to credit-impaired losses and economic factors.
  • Despite challenges, the company’s core business remains stable with a projected net profit.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Kindstar Globalgene Issues Profit Warning Amid Economic Challenges

Don’t Miss TipRanks’ Half-Year Sale

Kindstar Globalgene Technology, Inc. ( (HK:9960) ) has provided an announcement.

Kindstar Globalgene Technology, Inc. has issued a profit warning, expecting to report a loss between RMB55 million and RMB65 million for the year ending December 31, 2024, compared to a profit of RMB36.4 million in the previous year. The anticipated losses are attributed to significant credit-impaired losses from prolonged accounts receivable cycles, economic downturn impacts, intensified industry competition, and strategic adjustments affecting net income. Despite these challenges, the company’s core business remains stable, projecting a net profit of RMB30 million to RMB35 million, excluding certain losses.

More about Kindstar Globalgene Technology, Inc.

Kindstar Globalgene Technology, Inc. operates in the medical testing industry, focusing on specialty esoteric testing as its core business. The company is actively exploring prospective areas within this field to enhance its market position.

YTD Price Performance: 20.34%

Average Trading Volume: 2,109,758

Technical Sentiment Consensus Rating: Hold

Current Market Cap: HK$1.44B

For a thorough assessment of 9960 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1